RxDoctor Payments Data

Mohammad Arshad, DO

Adult Medicine · Harwich, MANPI 1386730158

Payments from drug & device makers

What this record shows

10 manufacturers reported payments, led by Spineology Inc. at 41.0% of the total.

$831in general payments, 2019–2025

Across 32 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spineology Inc.$341
  • Pfizer$171
  • AstraZeneca$99
  • Novo Nordisk$96
  • Boehringer Ingelheim$42
  • AbbVie$23
  • plus $58 from 4 others

What the payments were for

  • Travel & lodging$34141%
  • Food & beverage$49059%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult medicine providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$80,469
Medicare patients
220
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$27,705
JanuviaSitagliptin Phosphate12$11,872
Breo ElliptaFluticasone/Vilanterol16$8,374
XareltoRivaroxaban13$7,027
Levothyroxine Sodium297$5,766
Atorvastatin Calcium360$5,222
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,944
Tresiba Flextouch U-100Insulin Degludec14$4,379
Wixela InhubFluticasone Propion/Salmeterol37$3,220
Metoprolol Succinate115$3,056
Omeprazole149$2,769
Olmesartan Medoxomil52$2,464
Rosuvastatin Calcium53$2,459
Losartan Potassium170$2,010
Albuterol Sulfate HfaAlbuterol Sulfate39$2,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$171$27,70541 claims
GSKBreo Ellipta$12$8,37416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Massachusettson file to place this against a meaningful peer group, so we don't.

Other adult medicine in Harwich

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →